Roots Analysis

FEBRUARY 26, 2024

Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

Roots Analysis

FEBRUARY 24, 2022

Owing to the incessant demand for oligonucleotide-based products, several small to mid-sized companies and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers. The post Accelerating Oligonucleotide Demand: A Force Driving The Contract Manufacturing Market appeared first on Blog.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing Drug Delivery Systems 52

Roots Analysis

FEBRUARY 14, 2023

Presently, outsourcing of liposomes development and manufacturing related services has become a popular practice. Drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise.

Development 52

Development Manufacturing Drug Delivery Systems Contract Manufacturing 52

Roots Analysis

FEBRUARY 20, 2022

Amidst the current initiatives to develop therapeutic interventions with improved bioavailability, nanoparticles have specifically captured the interest of researchers and drug developers, given their ability to act as drug carriers for complex and highly promising therapeutics. Nanoparticles Contract Manufacturing.

Contract Manufacturing 52

Contract Manufacturing Bioavailability Manufacturing Drug Delivery Systems 52

Roots Analysis

MARCH 13, 2022

Therefore, a variety of excipients, which are pharmacologically inert substances themselves, are used to stabilize biologics during the manufacturing process and storage. The Evolving Landscape of Biopharmaceutical Excipient Manufacturing Domain. Biopharmaceutical excipients can range from simple inert entities to complex compounds.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

FEBRUARY 13, 2023

Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. As a result, there is an evident increase in the demand for mRNA manufacturing capacity.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52